Drug Trial Radar · NCT07011043
A Phase 1b Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
Last checked: Nov 19, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Jul 10, 2025
Primary completion
Apr 2027
Study completion Apr 2027
Sponsor
- Lead sponsor
- Climb Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 8, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main objective is to assess the safety and tolerability of budoprutug in adults with SLE. Pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy will also be assessed.
Conditions
- Systemic Lupus Erythematosus
Interventions
BudoprutugDrug
Single IV dose of study product on Day 1 of study
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 24
- Incidence of Clinical Laboratory AbnormalitiesTime frame: Up to Week 24
- Change from Baseline in Systolic Blood PressureTime frame: Up to Week 24
- Change from Baseline in Diastolic Blood PressureTime frame: Up to Week 24
- Change from Baseline in Heart RateTime frame: Up to Week 24
- Change from Baseline in Respiratory RateTime frame: Up to Week 24
- Change from Baseline in Body TemperatureTime frame: Up to Week 24
- Change from Baseline in PR IntervalTime frame: Up to Week 24
- Change from Baseline in QRS DurationTime frame: Up to Week 24
- Change from Baseline in QT IntervalTime frame: Up to Week 24
- Change from Baseline in QTc IntervalTime frame: Up to Week 24
Locations
18 sites in 8 countries. Site status is shown where the registry gives one.
Climb Bio Investigative Site #100104
Allen, Texas · Recruiting
Climb Bio Investigative Site #100101
San Antonio, Texas · Recruiting
Climb Bio Investigative Site# 359101
Plovdiv, Bulgaria · Recruiting
Climb Bio Investigative Site# 359102
Sofia, Bulgaria · Recruiting
Climb Bio Investigative Site #995102
Tbilisi, Georgia · Recruiting
Climb Bio Investigative Site #995101
Tbilisi, Georgia · Recruiting
Climb Bio Investigative Site# 300102
Exochi, Thessaloniki, Greece · Recruiting
Climb Bio Investigative Site# 300103
Thessaloniki, Thessaloniki, Greece · Recruiting
Climb Bio Investigative Site #100103
Caguas, Puerto Rico · Recruiting
Climb Bio Investigative Site# 400101
Cluj-Napoca, Romania · Recruiting
Climb Bio Investigative Site# 340102
A Coruña, Spain · Recruiting
Climb Bio Investigative Site# 340101
Sabadell, Barcelona, Spain · Recruiting
Climb Bio Investigative Site #380102
Ivano-Frankivsk, Ukraine · Recruiting
Climb Bio Investigative Site #380103
Kyiv, Ukraine · Recruiting
Climb Bio Investigative Site #380106
Kyiv, Ukraine · Recruiting
Climb Bio Investigative Site #380101
Ternopil, Ukraine · Recruiting
Climb Bio Investigative Site #380104
Vinnytsia, Ukraine · Recruiting
Climb Bio Investigative Site #380105
Vinnytsia, Ukraine · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.